Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis

Multiple Sclerosis

Volumn 12, Issue 2, 2006, Pages 143-148

  Brettschneider, J ^a   Petzold, A ^b   Junker, A ^a   Tumani, Hayrettin ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Axonal damage; Cerebrospinal fluid; Clinically isolated syndrome; Multiple sclerosis neurofilaments; Tau protein

Indexed keywords

NEUROFILAMENT PROTEIN; TAU PROTEIN;

ADOLESCENT; ADULT; ARTICLE; AXONAL INJURY; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AXONS; DISEASE PROGRESSION; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SPINAL CORD; SYNDROME; TAU PROTEINS;

EID: 33645806333     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1263oa     Document Type: Article

References (36)

1. Tintore M, Rovira A, Brieva L, Grive E, Jardi R, Borras C et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult Scler 2001; 7: 359-63.
2. Fazekas F, Offenbacher H, Fuchs S, Schmidt R, Niederkorn K, Horner S et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988; 38: 1822-25.
3. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-69.
4. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996; 119: 701-708.
5. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93.
6. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121: 1469-77.
7. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
8. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123: 1174-83.
9. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-12.
10. Van Waesberghe JH, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R et al. Axonal loss in multiple sclerosis: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46: 747-54.
11. Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol 1985; 101: 1371-78.
12. Teunissen CE, Dijkstra PC, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005; 4: 32-41.
13. Sussmuth SD, Reiber H, Tumani H. Tau protein in cerebrospinal fluid (CSF): a blood?CSF barrier related evaluation in patients with various neurological diseases. Neurosci Lett 2001; 300: 95-98.
14. Kapaki E, Paraskevas GP, Michalopoulou M, Kilidireas K. Increased cerebrospinal fluid tau protein in multiple sclerosis. Eur Neurol 2000; 43: 228-32.
15. Bartosik-Psujek H, Archelos JJ. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol 2004; 251: 414-20.
16. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 402-404.
17. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003; 278: 179-90.
18. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002; 122: 132-39.
19. Lim ET, Grant D, Pashenkov M, Keir G, Thompson EJ, Soderstrom M et al. Cerebrospinal fluid levels of brain specific proteins in optic neuritis. Mult Scler 2004; 10: 261-65.
20. Petzold A, Rejdak K, Plant GT. Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry 2004; 75: 1178-80.
21. Brettschneider J, Maier M, Arda S, Claus A, Süssmuth SD, Kassubek J et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler 2005 (in press).
22. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FB et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
23. Hickman S, Dalton C, Miller D, Plant GT. Management of acute optic neuritis. Lancet 2002; 360: 1953-62.
24. Poser CM, Paty DW, Scheiberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
25. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
26. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61: 1828-34.
27. Keir G, Luxton RW, Thompson EJ. Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update. Ann Clin Biochem 1990; 27: 436-43.
28. Stöhr M, Dichgans J, Buettner UW, Hess CW. Evozierte potentiale. Springer, 1996.
29. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901.
30. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001; 357: 1576-82.
31. Tintore M, Rovira A, Rio J, Nos C, Grive E, Tellez N et al. Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol 2005; 57: 210-15.
32. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720-25.
33. Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004; 63: 1586-90.
34. Eikelenboom MJ, Petzold A, Lazeron RH, Silber E, Sharief M, Thompson EJ. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003; 60: 219-23.
35. Thompson AJ, Kermode AG, MacManus DG, McDonald WI. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. Br Med J 1990; 300: 631-34.
36. Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR et al. Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996; 47: 1469-76.